Note: Separate PDQ summaries on Liver (Hepatocellular) Cancer Screening; Adult Primary Liver Cancer Treatment; Childhood Liver Cancer Treatment; and Levels of Evidence for Cancer Screening and Prevention Studies are also available.
Based on solid evidence, immunizing individuals against hepatitis B would lead to a decrease in the incidence of hepatocellular cancer (HCC).
Hepatocellular cancer (HCC) is the fifth most common cancer in the world in men and the second leading cause of cancer mortality worldwide. In women, hepatocellular cancer is the seventh most common cancer and the sixth leading cause of cancer mortality worldwide.  Age-standardized incidence rates are 2.1 per 100,000 population in North America.  In the United States, HCC incidence and mortality rates continue to increase, particularly among middle-aged black, Hispanic, and white men. 
It is estimated that there will be 40,710 new cases diagnosed and 28,920 deaths due to this disease in the United States in 2017.  There is a distinct male preponderance among all ethnic groups in the United States, although this trend is most marked among Asians/Pacific Islanders, in whom the annualized rate of HCC is 20.2 per 100,000 population among men and 7.6 per 100,000 population among women.  Table 1 summarizes the incidence of HCC by geographic region. 
In the United States, chronic hepatitis B is the underlying cause of an estimated 2,000 to 4,000 deaths each year from cirrhosis and liver cancer; it is estimated that more than one million Americans have a chronic hepatitis B infection, many of whom do not know they are infected. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are among the most frequent viral infections in humans and represent a major global public health problem. HBV- and HCV-related chronic hepatitis are the main causes of cirrhosis and HCC, which are responsible for a high rate of morbidity and mortality. In the last few years, knowledge of the epidemiology and the natural history of HBV and HCV infections has markedly improved, and considerable progress has been made in the efficacy of therapy.
|Region||Incidence (per 100,000 population)|
|aAdapted from Russo et al. |
HCC is very rare in persons younger than 40 years in the United States, and a much higher risk of HCC is associated with a long duration of infection with hepatitis C (e.g., greater risk after 30 years of infection). About 80% of persons with HCC have cirrhosis. 
There are several types of viruses associated with hepatitis and/or HCC. Hepatitis is also the name of a family of viral infections that affect the liver; the most common types are hepatitis A, hepatitis B, and hepatitis C. 
|Hepatic Virus Types||Mode of Transmission||Clinical Consequences|
|Hepatitis A||Food, drinking water. Little or no association with cancer.||Full recovery (usually)|
|Hepatitis B||Body fluids, e.g., blood, semen||Can cause liver damage; can result in acute or chronic HCC|
|Hepatitis C||Body fluids, e.g., blood, semen||Acute hepatitis and chronic liver disease, including cirrhosis and liver cancer|
|Hepatitis D||Body fluids, e.g., blood, semen||Acute hepatitis|
|Hepatitis E||Infected drinking water|
|Hepatitis F||No virus confirmed|
|Hepatitis G||To be determined|
Hepatitis A, hepatitis B, and hepatitis C are diseases caused by three different viruses. Although each disease can cause similar symptoms, the diseases have different modes of transmission and can affect the liver differently.
Hepatitis A appears only as an acute or newly occurring infection and does not become chronic. People with hepatitis A usually improve without treatment. 
Hepatitis B and hepatitis C can also begin as acute infections, but in some people, the virus remains in the body, resulting in chronic disease and long-term liver problems. There are vaccines to prevent hepatitis A and B; however, there is not a vaccine for hepatitis C. If a person has had one type of viral hepatitis in the past, it is still possible to get the other types. 
After the hepatitis A and hepatitis B viruses were discovered, neither agent was found responsible for many cases of transfusion-related hepatitis—hence the designation non-A, non-B (NANB) hepatitis. Initial follow-up of these cases showed that approximately 50% of patients developed chronic hepatitis, based on persistence of serum enzymes for at least 6 months. Approximately 15 years later, after HCV had been identified as the cause of NANB hepatitis, chronic hepatitis was found to develop more frequently as indicated by persistent viral infection in more than 80% of infected adults but in only about 50% of infected children or young women. 
Hepatitis A is caused by eating food and drinking water infected with a virus called HAV. It does not lead to chronic or lifelong disease. Almost everyone who develops hepatitis A has a full recovery.
Hepatitis B is caused by the virus HBV, which is spread by contact with an infected person's blood, semen, or other body fluid. It is a sexually transmitted disease. Hepatitis B can be a serious infection that can cause liver damage, which may result in cancer.  
Hepatitis C is of concern to both industrialized and developing countries. 
Hepatitis C liver disease ranges in severity from a mild illness lasting a few weeks to a serious, lifelong illness that attacks the liver. Hepatitis C results from infection with HCV, which is spread primarily through contact with the blood of an infected person. Hepatitis C can be either acute or chronic.  Most people who have hepatitis C develop a chronic infection; this may lead to a scarring of the liver, called cirrhosis. Blood banks test all donated blood for both hepatitis B and hepatitis C, which greatly reduces the risk of getting the virus from blood transfusions or blood products.    
Hepatitis D is caused by the virus HDV. A person can only get hepatitis D if they are already infected with hepatitis B. It is spread through contact with infected blood, dirty needles, and unprotected sex with a person infected with HDV. Hepatitis D causes swelling of the liver.  
Hepatitis E is caused by the hepatitis E virus. Hepatitis E can be spread through oral-anal contact or by drinking infected water.  This type of hepatitis does not occur often in the United States.
Chronic hepatitis G infection is not associated with HCC in either hepatitis B surface antigen-positive carriers or noncarriers.  
Chronic hepatitis B and chronic hepatitis C (CHC) are recognized as the major factors worldwide that increase the risk of HCC, with risk being greater in the presence of coinfection.       The incidence of HCC in individuals with chronic hepatitis is as high as 0.46% per year. In the United States, chronic hepatitis B and CHC account for about 30% to 40% of HCC. Long-term iron depletion in CHC patients has been studied as a modality for lowering the risk of progression to HCC.  Iron depletion improves serum alanine aminotransferase levels and hepatic oxidative DNA damage. In a cohort study of biopsy-proven CHC patients with moderate or severe liver fibrosis, patients were divided into two groups. Patients in group A (n = 35) underwent weekly phlebotomy (200 g) until they reached a state of mild iron deficiency, followed by monthly maintenance phlebotomy for 44 to 144 months (median, 107 months), and were advised to consume a low-iron diet (5–7 mg iron/day).  Group B (n = 40) comprised CHC patients who declined to receive iron depletion therapy. Both groups included patients who failed to respond to previous interferon (IFN) therapy or had conditions for which IFN was contraindicated. Hepatocarcinogenesis rates in groups A and B were 5.7% and 17.5% at the end of the fifth year and 8.6% and 39% in the tenth year, respectively. 
Cirrhosis is a risk factor for HCC, irrespective of the etiology of the cirrhosis.   The annual risk of developing HCC among persons with cirrhosis is between 1% and 6%.  Other risk factors include hemochromatosis, alpha-1-antitrypsin deficiency, glycogen storage disease, porphyria cutanea tarda, tyrosinemia, and Wilson disease,  but rarely biliary cirrhosis.  Aflatoxins, which are mycotoxins formed by certain Aspergillus species, are a frequent contaminant of improperly stored grains and nuts. In parts of Africa, the high incidence of HCC in humans may be related to ingestion of foods contaminated with aflatoxins. This association, however, is blurred by the frequent coexistence of hepatitis B infection in those population groups. Heavy aflatoxin exposure is associated with inactivation of the p53 tumor suppressor gene, but epidemiological evidence of a causal association is limited.  The likely etiology of HCC is summarized in Table 3. 
|Causative Agents||Dominant Geographical Areas|
|Hepatitis B virus||Asia and Africa|
|Hepatitis C virus||Europe, United States, and Japan|
|Alcohol||Europe and United States|
|Aflatoxins||East Asia and Africa|
Strong evidence that hepatocellular cancer (HCC) can be prevented is provided by a cluster randomized controlled trial of the immunization of 75,000 newborns with hepatitis B virus (HBV) vaccine. After a median of about 25 years of follow-up, the incidence ratio of primary liver cancer in the vaccination-at-birth group to the control group (68% of whom received catch-up vaccinations at ages 10–14 years) was 0.16 (95% confidence interval, 0.03–0.77).  These findings suggest that if HBV can be prevented, then much HCC can be prevented. Immunization programs are already known to prevent important short-term consequences of hepatitis B infection, such as acute hepatitis, chronic hepatitis, and cirrhosis.
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Updated statistics with estimated new cases and deaths for 2017 (cited American Cancer Society as reference 4 and Howlader et al. as reference 5).
This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about liver (hepatocellular) cancer prevention. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.
This summary is reviewed regularly and updated as necessary by the PDQ Screening and Prevention Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).
Board members review recently published articles each month to determine whether an article should:
Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.
Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's Email Us. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.
Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Screening and Prevention Editorial Board uses a formal evidence ranking system in developing its level-of-evidence designations.
PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”
The preferred citation for this PDQ summary is:
PDQ® Screening and Prevention Editorial Board. PDQ Liver (Hepatocellular) Cancer Prevention. Bethesda, MD: National Cancer Institute. Updated <MM/DD/YYYY>. Available at: https://www.cancer.gov/types/liver/hp/liver-prevention-pdq. Accessed <MM/DD/YYYY>. [PMID: 26389403]
Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online, a collection of over 2,000 scientific images.
The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the Managing Cancer Care page.
More information about contacting us or receiving help with the Cancer.gov website can be found on our Contact Us for Help page. Questions can also be submitted to Cancer.gov through the website’s Email Us.Date first published: 2005-05-23 Date last modified: 2017-05-03